Skip to main content
Quest Diagnostics

Analytical Validation and Performance Characteristics of a 523-Gene Next-Generation Sequencing Panel for Comprehensive Genomic Profiling in Solid Tumors

AMP 2023

Association for Molecular Pathology

Salt Lake City, UT, Nov 14-18 2023

Poster presentation: Analytical Validation and Performance Characteristics of a 523-Gene Next-Generation Sequencing Panel for Comprehensive Genomic Profiling in Solid Tumors

Authors: Acab A, Neishaboori N, Ma C, Gonong B,Toliver V, Racke F, Godsey J

Specialty: Oncology

Related conttent

Publication
Sporadic Oncocytic Tumors with Features Intermediate between Oncocytoma and Chromophobe
Validation and adoption of an IGVH mutational status assay in chronic lymphocytic leukemia (CLL) using next-generation sequencing (NGS) in a clinical laboratory
Conference Presentation
Highly specific copy number variant flagging algorithm using next generation sequencing in cancer predisposition genes
Publication
Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Test FAQ
Solid Tumor Core Panel
Test FAQ
Solid Tumor Expanded Panel

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.